Latest News

West Des Moines, Iowa – Born in 2013, identical twins Kenzie and Kaylie Morell were hitting some, if not all, of their normal infant and toddler milestones—until they began to slip back from them. When Kenzie was around 15 months old, she started to regress. Kaylie followed a year and...
Lund – Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the first subject has been dosed in phase I clinical study of the newly developed eye-drop formulation of the company’s candidate drug laquinimod. Laquinimod is being developed as a new treatment for non-infectious non-anterior uveitis and has the potential to...
BOCA RATON, Fla. — First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that it has entered a non-binding term sheet to sell its Niclosamide program for the treatment of inflammatory bowel diseases (IBD) such as ulcerative...
The Gamida Cell-Teva Joint Venture announced today that five prestigious cord blood transplantations centers in Spain, three in Barcelona and two in Valencia, have joined the ExCell study. Participating clinical sites include, in alphabetical order: * Hospital Clínic of Barcelona, Barcelona: Principal Investigator, Dr. Enric Carreras, MD * Hospital Clínico...
Trent Hills – How many five-year-olds can say they’ve thrown the ceremonial first pitch at a Blue Jay game the night the team’s ace pitcher Roy Halladay is honoured as Sportsperson of the Year, or shared the stage with international pop star John Mayer at a concert in Toronto? Isaac...
LEUVEN, Belgium, STRASBOURG, France, and PHILADELPHIA — Flamingo Therapeutics (“Flamingo”) today announced the appointment of Andrew E. Denker, MD, PhD., as Chief Medical Officer. Dr. Denker is a physician-scientist with over two decades of biotech and pharmaceutical industry experience in clinical development across multiple modalities and therapeutic areas, including oncology...
CAMBRIDGE, Mass. — Flare Therapeutics Inc., a biotechnology company targeting transcription factors (TF) to discover precision medicines for cancer and other diseases, announced the presentation of data regarding the Phase 1 clinical trial design of FX-909, a highly potent and selective inhibitor of PPARG. “FlareTx has built a robust body...
FORT MYERS, Fla. — A best practices program developed at Florida Cancer Specialists & Research Institute (FCS) has been shown to improve outcomes for adult patients prescribed selinexor for the treatment of relapsed/refractory multiple myeloma (RRMM). Results obtained from a one-year retrospective observational study using data collected by FCS’ Real-World...